This study examined adalimumab (ADL) therapeutic medication monitoring in paediatric patients with Crohn disease in clinic remission (CR) and in mucosal curing (MH) (CD). In addition, a 3-Year follow-up assessment was carried out on the long-term therapeutic effectiveness of ADL in paediatric CD. A prospective study of 31 CD patients receiving ADL maintenance treatment and endoscopic examination of MH and pharmacokinetic analysis was carried out. The Pediatric Crohn Disease Activity Index (PCDAI) has identified patients in CR with less than 10 scores. The Simple Endoscopic Scores for Crohn Disease (SES-CD) of less than 2 patients with MH have been identified.
At 4 months and 1 year of ADL treatment, 28 and 26 patients, respectively, had CR; 13 and 17 patients had MH. The median trough levels of ADL in patients in CR were greater than in individuals with active illness. Patients who achieved MH had significantly higher ADL TLs than those who did not. During long-term follow-up, ADL TLs were consistently maintained above 10 g/mL, and not only CR and MH, but also histologic remission, were achieved at a high rate. During the maintenance phase, ADL treatment had a beneficial effect on development. Long-term consistent effectiveness and beneficial impacts on the indicators of growth were shown in the ADL treatment.
